InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.14
(
-0.43%
)
Bitcoin
54,987.64
(
-1.54%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

xavierprivas

Send PM Follow Ignore
Followers 6
Posts 162
Boards Moderated 0
Alias Born 09/14/2009

xavierprivas

Re: DewDiligence post# 225919

Saturday, 08/17/2019 12:57:32 PM

Saturday, August 17, 2019 12:57:32 PM

Post# of 252504
Meanwhile BLCM (AKTX competitor in HSCT) already finished ph3 of BPX-501
meeting the primary endpoint in July (I am not examining their claim
critically at all - just pointing out their PR) while AKTX only threatens to
start ph3 of their drug in 4Q19 with not much cash.

BLCM has $60M cash at the end 2Q19 and they planned to get $139M more. Apparently
the market is not impressed with BPX-501 as BLCM has negative EV.
https://finance.yahoo.com/news/correcting-replacing-bellicum-pharmaceuticals-inc-145615808.html

I am pointing out the irrationality of Mr Market, NOT advocating
purchase of either AKTX or BLCM.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up